1. Myeloproliferative disorders Chris hatton

2. Proliferate or accumulative Bone marrow produces 10 11 cells – mainly erythrocytes Bone marrow produces 10 11 cells – mainly erythrocytes Production must be balanced by cell death – apoptosis Production must be balanced by cell death – apoptosis Myeloproliferative disorders are failures of apoptotic mechanisms Myeloproliferative disorders are failures of apoptotic mechanisms

3. The disorders Chronic myeloid leukaemia Chronic myeloid leukaemia Polycythaemia rubra vera Polycythaemia rubra vera Myelofibrosis Myelofibrosis Essential thrombocythaemia Essential thrombocythaemia

4. The Talk Background on CML following the introduction of Gleevec Background on CML following the introduction of Gleevec Essential thrombocythaemia and oral chemotherapy Essential thrombocythaemia and oral chemotherapy Polycythaemia rubra vera Polycythaemia rubra vera

5. Chronic myeloid leukaemia Chronic myeloid leukaemia (CML) is a rare disorder 4-6 new cases per year in Oxford Chronic myeloid leukaemia (CML) is a rare disorder 4-6 new cases per year in Oxford Presents Presents –Sweats, fever, wt loss –Hepatosplenomegaly –Bleeding/thrombosis –hyperleucocytosis

6. Laboratory findings Leucocytosis – occ very high 300-500 x 10 9 /l Leucocytosis – occ very high 300-500 x 10 9 /l Basophilia Basophilia Thrombocytosis Thrombocytosis Anaemia which corrects on treatment Anaemia which corrects on treatment

7. Chronic phase Median duration 5–6 years Accelerated phase Median duration 6–9 months Blast crisis Median survival 3–6 months CML: a Progressive and Fatal Disease

8. Treatment Options for CML Hydroxyurea Hydroxyurea Interferon Interferon Busulphan Busulphan Allogeneic Bone Marrow Transplant Allogeneic Bone Marrow Transplant

9. Cytogenetics and molecular biology Philadelphia chromosome Philadelphia chromosome –t(9 : 22) Novel gene Novel gene –BCR-ABL Novel protein Novel protein – tyrosine kinase Translocation leads to novel protein Faderl, S. et. al. N Engl J Med 1999;341:164-172

10. The Translocation of t(9;22)(q34;q11) in CML

11. Faderl, S. et. al. N Engl J Med 1999;341:164-172 Signaling Pathways of p210BCR-ABL

12. Goldman, J. M. et. al. N Engl J Med 2001;344:1084-1086 Likely Mode of Action of STI571

13. Gleevec- tyrosine kinase inhibitor Gleevec- tyrosine kinase inhibitor

14. Phase I Study: Gleevec® Achieves Hematologic and Cytogenetic Responses Typically 4 weeks to achieve CHR, 2 to 10 months to achieve MCR A maximal tolerated dose (MTD) was not reached (up to 1000mg/day ) Chronic Phase IFN-á Failure 300–1000mg/day(n=54) 100% 98% 31% 13% Blast Crisis, Myeloid 300–1000mg/day(n=38) 55% 11% Blast Crisis,Lymphoid 300–1000mg/day (n=20) 70% 20% 11% 8%

16. Druker, B. J. et. al. N Engl J Med 2001;344:1031-1037 Hematologic Responses in Six Patients Receiving 500 mg of STI571 per day

17. Gleevec Cost - £64 PER DAY Cost - £64 PER DAY £15,000 PER ANNUM PER PATIENT £15,000 PER ANNUM PER PATIENT NICE APPROVED NICE APPROVED

18. Gleevec Leukemia drug Gleevec slows accumulation of major component of senile plaques in cell studies and in guinea pigs ! September 2003

19. Polycythaemia Elevated haemoglobin Elevated haemoglobin normal PRV Stress Secondary

20. Polycythaemia rubra vera Red cell life span is not prolonged in PRV Red cell life span is not prolonged in PRV Multipotent stem cell Multipotent stem cell Renal failure does not suppress Renal failure does not suppress Hypoxia does not drive it further Hypoxia does not drive it further Phlebotomy does not accelerate it Phlebotomy does not accelerate it Low serum erythropoietin Low serum erythropoietin

21. Polycythaemia rubra vera Reduction of the red cell mass and maintaining it at a safe level by phlebotomy (hematocrit level of < 45% in men and < 42% in women and < 36% during pregnancy) is the first principle of therapy in polycythemia vera. Reduction of the red cell mass and maintaining it at a safe level by phlebotomy (hematocrit level of < 45% in men and < 42% in women and < 36% during pregnancy) is the first principle of therapy in polycythemia vera. Venesection is a safe and immediately effective therapy and its desired side effect, iron deficiency, is not a liability, claims that cannot be made for any of the surrogate therapies for polycythemia vera that have been proposed to date. Venesection is a safe and immediately effective therapy and its desired side effect, iron deficiency, is not a liability, claims that cannot be made for any of the surrogate therapies for polycythemia vera that have been proposed to date. Reduction of the red cell mass and maintaining it at a physiologic level removes a major source of complications and may also alleviate systemic hypertension and pruritus and reduce splenomegaly. Reduction of the red cell mass and maintaining it at a physiologic level removes a major source of complications and may also alleviate systemic hypertension and pruritus and reduce splenomegaly.

22. Polycythaemia rubra vera For many patients, no other therapy may be necessary for many years. Aspirin or anticoagulants such as warfarin are not substitutes for adequate phlebotomy. For many patients, no other therapy may be necessary for many years. Aspirin or anticoagulants such as warfarin are not substitutes for adequate phlebotomy. Occasionally, with blood loss or overzealous phlebotomy, symptomatic anemia can ensue. Judicious iron replacement can accelerate the recovery process but too much iron will result in an explosive increase in red cell mass. Occasionally, with blood loss or overzealous phlebotomy, symptomatic anemia can ensue. Judicious iron replacement can accelerate the recovery process but too much iron will result in an explosive increase in red cell mass.

23. Polycythaemia rubra vera Microvascular occlusive or hemorrhagic phenomenon Microvascular occlusive or hemorrhagic phenomenon Hyperuricemia, Hyperuricemia, Pruritus and acid-peptic disease, Pruritus and acid-peptic disease, Aspirin alone or anagrelide may be sufficient to combat the microvascular occlusive syndrome associated with thrombocytosis. Aspirin alone or anagrelide may be sufficient to combat the microvascular occlusive syndrome associated with thrombocytosis. A modest leukocytosis requires no correction; however, if progressive, leukocytosis is a harbinger of extramedullary hematopoiesis or disease acceleration. In which case, the leukocytosis can serve as a guide to disease control following the institution of therapy. A modest leukocytosis requires no correction; however, if progressive, leukocytosis is a harbinger of extramedullary hematopoiesis or disease acceleration. In which case, the leukocytosis can serve as a guide to disease control following the institution of therapy.

24. Spivak, J. N Engl J Med 2004;350:99-101 Thrombosis and PRV

25. Essential thrombocythaemia Disorder of the elderly Disorder of the elderly Diagnosis of exclusion Diagnosis of exclusion –reactive causes –Bleeding –Inflammation –malignancy High incidence of thrombotic complications High incidence of thrombotic complications – cerebral – myocardial – peripheral arterial thromboses – pulmonary embolism and deep-vein thrombosis are less frequent.

26. Essential thrombocythaemia Thrombocytosis and abnormal platelet function may contribute to the complications, but there is no clear evidence that they do. Thrombocytosis and abnormal platelet function may contribute to the complications, but there is no clear evidence that they do. Two thirds of patients with essential thrombocythemia are asymptomatic Two thirds of patients with essential thrombocythemia are asymptomatic High vascular-complication rate among patients older than 60 years and patients who had already had a thrombotic event. Such patients could be candidates for treatment to reduce their platelet counts. High vascular-complication rate among patients older than 60 years and patients who had already had a thrombotic event. Such patients could be candidates for treatment to reduce their platelet counts.

27. Treatment of ET Physicians often use hydroxyurea for the initial treatment of essential thrombocythemia. Physicians often use hydroxyurea for the initial treatment of essential thrombocythemia. This drug has a broad dose–response range, mild side effects, and theoretically little mutagenic risk. This drug has a broad dose–response range, mild side effects, and theoretically little mutagenic risk. Discontinuation of the drug quickly reverses any unwanted myelosuppression. Discontinuation of the drug quickly reverses any unwanted myelosuppression. Although hydroxyurea reduces the platelet count, there is no convincing evidence that it also decreases thrombotic episodes in patients with essential thrombocythemia. Although hydroxyurea reduces the platelet count, there is no convincing evidence that it also decreases thrombotic episodes in patients with essential thrombocythemia. Indeed, no clear relation has been established in this disease between the absolute platelet count and the frequency of thrombosis. Moreover, hydroxyurea, which does not permanently control the thrombocytosis, must be given indefinitely. Indeed, no clear relation has been established in this disease between the absolute platelet count and the frequency of thrombosis. Moreover, hydroxyurea, which does not permanently control the thrombocytosis, must be given indefinitely. This arouses concern because of the leukemogenic potential of hydroxyurea and clouds estimates of the drug's risk–benefit ratio. This arouses concern because of the leukemogenic potential of hydroxyurea and clouds estimates of the drug's risk–benefit ratio.

28. ET Young patients with very high platelet counts Young patients with very high platelet counts Pregnant women Pregnant women